{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:13:06Z","timestamp":1761394386930},"reference-count":18,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirality"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Oxcarbazepine is a second\u2010generation antiepileptic drug indicated as monotherapy or adjunctive therapy in the treatment of partial seizures or generalized tonic\u2013clonic seizures in adults and children. It undergoes rapid presystemic reduction with formation of the active metabolite 10\u2010hydroxycarbazepine (MHD), which has a chiral center at position 10, with the enantiomers (S)\u2010(+)\u2010 and R\u2010(\u2212)\u2010MHD showing similar antiepileptic effects. This study presents the development and validation of a method of sequential analysis of oxcarbazepine and MHD enantiomers in plasma using liquid chromatography with tandem mass spectrometry (LC\u2010MS\/MS). Aliquots of 100\u2009\u03bcL of plasma were extracted with a mixture of methyl <jats:italic>tert<\/jats:italic>\u2010butyl ether: dichloromethane (2:1). The separation of oxcarbazepine and the MHD enantiomers was obtained on a chiral phase Chiralcel OD\u2010H column, using a mixture of hexane:ethanol:isopropanol (80:15:5, v\/v\/v) as mobile phase at a flow rate of 1.3\u2009mL\/min with a split ratio of 1:5, and quantification was performed by LC\u2010MS\/MS. The limit of quantification was 12.5\u2009ng oxcarbazepine and 31.25\u2009ng of each MHD enantiomer\/mL of plasma. The method was applied in the study of kinetic disposition of oxcarbazepine and the MHD enantiomers in the steady state after oral administration of 300\u2009mg\/12\u2009h oxcarbazepine in a healthy volunteer. The maximum plasma concentration of oxcarbazepine was 1.2\u2009\u00b5g\/mL at 0.75\u2009h. The kinetic disposition of MHD is enantioselective, with a higher proportion of the S\u2010(+)\u2010MHD enantiomer compared to R\u2010(\u2212)\u2010MHD and an AUC<jats:sup>0\u201012<\/jats:sup> <jats:sub>S\u2010(+)\/R\u2010(\u2212)<\/jats:sub> ratio of 5.44. <jats:italic>Chirality 25:897\u2013903, 2013<\/jats:italic>. \u00a9 2013 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/chir.22231","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T01:35:14Z","timestamp":1381541714000},"page":"897-903","source":"Crossref","is-referenced-by-count":13,"title":["Analysis of Oxcarbazepine and the 10\u2010Hydroxycarbazepine Enantiomers in Plasma by LC\u2010MS\/MS: Application in a Pharmacokinetic Study"],"prefix":"10.1002","volume":"25","author":[{"given":"Natalicia","family":"de Jesus Antunes","sequence":"first","affiliation":[{"name":"Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauro","family":"Wichert\u2010Ana","sequence":"additional","affiliation":[{"name":"Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Barbosa","family":"Coelho","sequence":"additional","affiliation":[{"name":"Departamento de Cl\u00ednica M\u00e9dica, Faculdade de Medicina de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Della Pasqua","sequence":"additional","affiliation":[{"name":"Division of Pharmacology Leiden Academic Centre for Drug Research  Leiden The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Veriano","family":"Alexandre","sequence":"additional","affiliation":[{"name":"Departamento de Neuroci\u00eancias e Ci\u00eancias do Comportamento, Faculdade de Medicina de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osvaldo Massaiti","family":"Takayanagui","sequence":"additional","affiliation":[{"name":"Departamento de Neurologia, Psiquiatria e Psicologia M\u00e9dica, Faculdade de Medicina de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Tozatto","sequence":"additional","affiliation":[{"name":"Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[{"name":"Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas, Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto Universidade de S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115020-00005"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.030593"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb05967.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10\u2010hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects","volume":"66","author":"Volosov A","year":"1999","journal-title":"Clin Pharmacol Therap"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(99)00531-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342120-00002"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(92)80459-4"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00315422"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb00918.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/00498258609043567"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.10.025"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318058a2c2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1670"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.05.013"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.07.019"},{"key":"e_1_2_6_17_1","unstructured":"Ag\u00eancia Nacional de Vigilncia Sanit\u00e1ria (ANVISA):Resolution RDC no. 27 dated May 17 2012. Di\u00e1rio Oficial May 222012."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03595.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1510"}],"container-title":["Chirality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fchir.22231","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.22231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T01:58:18Z","timestamp":1696643898000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/chir.22231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":18,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1002\/chir.22231"],"URL":"https:\/\/doi.org\/10.1002\/chir.22231","archive":["Portico"],"relation":{},"ISSN":["0899-0042","1520-636X"],"issn-type":[{"value":"0899-0042","type":"print"},{"value":"1520-636X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}